Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

June 17, 2024

https://www.globenewswire.com/news-release/2024/06/17/2899579/0/en/Enlivex-Announces-Positive-Interim-Data-Readout-from-a-Phase-I-II-Trial-Evaluating-Allocetra-in-End-Stage-Knee-Osteoarthritis.html

Key Highlights

Ness-Ziona, Israel, June 17, 2024 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq:ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today released a positive interim data readout from a Phase I/II investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis who had been indicated for knee replacement surgery.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.